Affinity Asset Advisors’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.9M	Buy	500,000 +150,000	+43%	+$4.09M	0.93%	34
2025 Q4	$9.51M	Buy	350,000 +50,000	+17%	+$1.32M	0.68%	46
2025 Q3	$7.76M	Buy	+300,000	New	+$6.95M	0.72%	41
2025 Q1	–	Sell	-9,992	Closed	-$252K	–	107
2024 Q4	$252K	Sell	9,992 -115,008	-92%	-$3.12M	0.04%	77
2024 Q3	$4.25M	Sell	125,000 -350,400	-74%	-$13.4M	0.66%	47
2024 Q2	$17.6M	Sell	475,400 -34,600	-7%	-$1.31M	2.77%	11
2024 Q1	$21.4M	Buy	510,000 +110,000	+28%	+$4.52M	3.48%	9
2023 Q4	$15.9M	Buy	400,000 +250,000	+167%	+$7.35M	3.16%	11
2023 Q3	$4.13M	Buy	150,000 +62,969	+72%	+$1.97M	1.35%	29
2023 Q2	$2.95M	Buy	87,031 +37,031	+74%	+$1.25M	1.16%	32
2023 Q1	$1.8M	Sell	50,000 -60,000	-55%	-$2.59M	0.69%	43
2022 Q4	$4.9M	Buy	110,000 +30,000	+38%	+$1.07M	2.25%	20
2022 Q3	$2.25M	Buy	80,000 +40,000	+100%	+$1.23M	1.04%	36
2022 Q2	$1.08M	Sell	40,000 -85,000	-68%	-$2.47M	0.59%	40
2022 Q1	$4.26M	Buy	125,000 +25,000	+25%	+$799K	1.69%	26
2021 Q4	$3.86M	Buy	100,000 +59,846	+149%	+$2.61M	1.65%	29
2021 Q3	$2.17M	Sell	40,154 -9,846	-20%	-$462K	0.86%	37
2021 Q2	$1.67M	Sell	50,000 -80,000	-62%	-$2.2M	0.8%	39
2021 Q1	$2.68M	Buy	130,000 +55,000	+73%	+$1.26M	1.31%	29
2020 Q4	$1.31M	Buy	+75,000	New	+$1.35M	0.81%	37